CSIMarket

Cephalon, Inc.  (CEPH)
Other Ticker:  
 
    Sector  Consumer Non Cyclical    Industry Legacy
   Industry Legacy
   Sector  Consumer Non Cyclical
 
Price: $0.0000 $0.00 %
Day's High: 0.00 Week Perf:
Day's Low: $ 0.00 30 Day Perf:
Volume (M): 0 52 Wk High: $ 0.00
Volume (M$): $ 0 52 Wk Avg: $0.00
Open: $0.00 52 Wk Low: $0.00



 Market Capitalization (Millions $) -
 Shares Outstanding (Millions) 88
 Employees -
 Revenues (TTM) (Millions $) 2,971
 Net Income (TTM) (Millions $) 553
 Cash Flow (TTM) (Millions $) 70
 Capital Exp. (TTM) (Millions $) -57

Cephalon, Inc.

Cephalon, Inc. is an international biopharmaceutical company dedicated to the discovery, development and marketing of innovative products to treat human diseases. We currently focus our efforts in four core therapeutic areas: central nervous system ("CNS") disorders, pain, oncology and addiction. In addition to conducting an active research and development program, we market seven proprietary products in the United States and numerous products in various countries throughout Europe. Consistent with our core therapeutic areas, we have aligned our approximately 690-person U.S. field sales and sales management teams by area. In Europe, we have a sales and marketing organization numbering approximately 400 persons that supports our presence in nearly 20 European countries, including France, the United Kingdom, Germany, Italy and Spain.

Our most significant product is PROVIGIL® (modafinil) Tablets [C-IV]. PROVIGIL is indicated for the treatment of excessive sleepiness associated with narcolepsy, obstructive sleep apnea/hypopnea syndrome ("OSA/HS") and shift work sleep disorder ("SWSD"). We co-promote PROVIGIL in the United States with our partner, Takeda Pharmaceuticals North America, Inc. Together with our CNS field sales team, we now have approximately 900 persons focused on detailing PROVIGIL in the United States.

Our two next most significant products are FENTORA® (fentanyl buccal tablet) [C-II] and ACTIQ® (oral transmucosal fentanyl citrate) [C-II] (including our generic version of ACTIQ ("generic OTFC")).

CUSTOMERS

Our principal customers are wholesale drug distributors. These customers comprise a significant part of the distribution network for all pharmaceutical products in the United States. Three large wholesale drug distributors, Cardinal Health, Inc., McKesson Corporation and AmerisourceBergen Corporation, control a significant share of this network. These three wholesale customers, in the aggregate, accounted for 66% of our total consolidated gross sales for the year ended December 31, 2007.

COMPETITION

We face intense competition and rapid technological change in the pharmaceutical marketplace. Large and small companies, academic institutions, governmental agencies, and other public and private research organizations conduct research, seek patent protection and establish collaborative arrangements for product development in competition with us. Products developed by any of these entities may compete directly with those we develop or sell. In addition, many of the companies and institutions that compete against us have substantially greater capital resources, research and development staffs and facilities than we have, and substantially greater experience in conducting clinical trials, obtaining regulatory approvals and manufacturing and marketing pharmaceutical products. These entities represent significant competition for us. Our products also face potential competition from companies seeking to develop and sell generic formulations of our products at a substantial price discount to the current price of our products. In addition, competitors who are developing products for the treatment of neurological or oncological disorders might succeed in developing technologies and products that are more effective than any that we develop or sell or that would render our technology and products obsolete or noncompetitive. Competition and innovation from these or other sources potentially could negatively affect sales of our products or make them obsolete. Advances in current treatment methods also may adversely affect the market for such products. In addition, we may be at a competitive marketing disadvantage against companies that have broader product lines and whose sales personnel are able to offer more complementary products than we can. Any failure to maintain our competitive position could adversely affect our business and results of operations.



   


Customers Net Income grew by CEPH's Customers Net Profit Margin fell to

10.08 %

4.51 %

• Customers Performance • Customers Expend. • Customers Efficiency • List of Customers


   

Stock Performances by Major Competitors

Year to Date Decrease / Increase
     
ABBV        9.31% 
ABT   -17.27%    
JNJ        4.61% 
LLY        11.36% 
MRK        22.06% 
PFE   -6.65%    
• View Complete Report
   



Nevada Canyon Gold Corp.

EPS Soared by Nevada Canyon Gold Corp in the first quarter of 2022 announcement

In the first quarter of 2022 Nevada Canyon Gold Corp earnings per share soared by 350 % of $0.09 per share compared to $0.02 a year ago and EPS turn positive from $-0.07 per share from the previous quarter.

Jupiter Wellness Inc.

Losses Widen by Jupiter Wellness Inc in the fiscal span ending Mar 31 2022 announcement

In the fiscal span ending Mar 31 2022 Jupiter Wellness Inc increased losses of $-0.13 per share compared to $0.00 a year ago and eps fell from $0.37 per share from the previous quarter.

Polarityte Inc.

Polarityte Inc reported first quarter of 2022 earnings season operating deficit of $-8.873 millions

In the first quarter of 2022 earnings season Polarityte Inc lost money of $-0.09 per share compared to $-0.24 a year ago and from $-0.00 per share from the previous quarter.

Citrine Global Corp

Sales and Earnings Unchanged

Citrine Global Corp announced operating deficit of $-0.34 millions, in the first quarter of 2022, an advancement from the operating loss of $-1.974725 millions, recorded in the same quarter a year ago.

Strategic Environmental and Energy Resources Inc.

Strategic Environmental And Energy Resources Inc reported softer Sales in the fiscal interval ending Mar 31 2022

In the fiscal interval ending Mar 31 2022 Strategic Environmental And Energy Resources Inc lost money of $-0.01 per share compared to $-0.01 a year ago and from $-0.01 per share from the previous quarter.






 

Cephalon's Segments
 
PROVIGIL
 Segment    34.4 % of total Revenue
GABITRIL
 Segment    1.36 % of total Revenue
Total CNS
 Segment    45.51 % of total Revenue
ACTIQ
 Segment    4.11 % of total Revenue
Generic OTFC
 Segment    0.82 % of total Revenue
FENTORA
 Segment    7.04 % of total Revenue
AMRIX
 Segment    1.86 % of total Revenue
Total Pain
 Segment    19.26 % of total Revenue
Oncology
 Segment    21.74 % of total Revenue
Other
 Segment    13.49 % of total Revenue
 
• View Complete Report
  Company Estimates  
  Revenue Outlook
Cephalon does not provide revenue guidance.

Earnings Outlook
Strategic Environmental and Energy Resources Inc. does not provide earnings estimates.

 
Geographic Revenue Dispersion
United States 76.3 %
International 23.7 %


       
Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

IWBB's Profile

Stock Price

IWBB's Financials

Business Description

Fundamentals

Charts & Quotes

IWBB's News

Suppliers

IWBB's Competitors

Customers & Markets

Economic Indicators

IWBB's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Cryptocurrencies

Sectors & Industries

Commodities

Currencies

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.    Copyright © 2022 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071